5PSQ-071 Efficacy and safety evaluation of trifluridine/tiparacil for metastatic colon cancer (mcrc)

BACKGROUND: Trifluridine/tiparacile is the second oral treatment approved for patients with mCRC who have received fluoropyrimidine, oxaliplin- and irinotecan-based chemotherapy, an anti-VEGF biologic therapy and, if RAS wild-type, an anti-EGFR. PURPOSE: To evaluate the efficacy and safety of patien...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Eur J Hosp Pharm
Prif Awduron: Herrera, S Guijarro, Domínguez, S Cano, Fumero, R García, Rodríguez-Hermida, F Artime, Soto, C Valencia, Zúñiga, L Gutiérrez, Morales, A Jiménez, García, C Collado
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BMJ Group 2018
Pynciau:
Section 5: Patient safety and quality assurance
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535737/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.425
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg